Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496571
Study type Interventional
Source Allakos, Inc.
Contact Henrik Rasmussen, MD, PhD
Phone 443-699-5230
Email hrasmussen@allakos.com
Status Recruiting
Phase Phase 2
Start date July 18, 2018
Completion date September 2019